The AIM All Share made a promising start but gains proved difficult to sustain and by late morning was trading in the red, lagging the main board. By 2.30pm the junior index was off by just a fraction of a point at 747.92.
- Genincode +31%
- Proteome Sciences +21%
- Caspian Sunrise +18%
- Physiomics -23%
- Deltic Energy -17%
Genincode LON:GENI was leading the pack at copy time, up 31%, with the gains coming off the back of news that the New York State department of health had approved a cardiac screening test developed by the company.
- AIM Market Roundup: Mosman Oil, Tekcapital, ECR Minerals
- AIM Market Roundup: Genincode, Silver Bullet, Focusrite
Proteome Sciences LON:PRM was 21% higher but there’s no news out here and with the spread being quoted at a whopping 60%, there’s little to underwrite the gains.
- AIM Market Roundup: Proteome Sciences, Greenroc Strategic Minerals, IQE
- AIM Market Roundup: Proteome Sciences, TAP Global, Various Eateries
Caspian Sunrise LON:CASP gets the notable mention, up 18%. The company this morning advised that it had obtained a license extension in Kazakhstan for a second site, the first having been renewed earlier in the year.
Physiomics LON:PYC was the biggest faller, off 23%, following news of a boardroom reshuffle. This won’t take place until well into next year and with results on track to meet expectations so the fall is arguably the market’s assessment of the fact the previous CEO is set to move from non-exec to executive chairman to bridge the gap whilst the business recruits a new CEO.
Deltic Energy LON:DELT slipped 17% as the acquiring party announced it had extended the long stop date on the deal by three months to end of March. Completion of the deal is still reliant on technical requirements including regulatory approval of change of control.
Comments (0)